

Tecentriq® (atezolizumab) - Expanded indication

- On May 18, 2020, Genentech announced the FDA approval of Tecentriq (atezolizumab), as a single agent, for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
 - This is the fourth approval for Tecentriq across NSCLC, including as a single agent or in combination with targeted therapies and/or chemotherapies.
- Tecentriq is also approved for urothelial cancer, triple-negative breast cancer, and small cell lung cancer.
- The approval of Tecentriq for the expanded indication was based on IMpower110, a randomized, open-label study in patients with stage IV NSCLC whose tumors express PD-L1, and who had received no prior chemotherapy for metastatic disease. Patients received Tecentriq or platinum-based chemotherapy. The major efficacy outcome measure was overall survival (OS) sequentially tested in the following subgroups of patients, excluding those with EGFR or ALK genomic tumor aberrations: TC ≥ 50% or IC ≥ 10%; TC ≥ 5% or IC ≥ 5%; and TC ≥ 1%, or IC ≥ 1%.
 - The trial demonstrated a statistically significant improvement in OS for patients with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) at the time of the OS interim analysis. Median OS was 20.2 months vs. 13.1 months for Tecentriq and platinum-based chemotherapy, respectively (hazard ratio: 0.59; 95% CI: 0.40, 0.89; p = 0.0106).
 - There was no statistically significant difference in OS for the other two PD-L1 subgroups (TC ≥ 5% or IC ≥ 5%; and TC ≥ 1% or IC ≥ 1%) at the interim or final analyses.
 - Median progression free survival (PFS) showed a HR of 0.63 (95% CI: 0.45, 0.88), with median PFS of 8.1 months in the Tecentriq arm and 5 months in the platinum-based chemotherapy arm.
 - The objective response rate was 38% (95% CI: 29, 48) in the Tecentriq arm and 29% (95% CI: 20, 39) in the platinum-based chemotherapy arm.
- The recommended dose of Tecentriq, when used as a single agent for NSCLC, is 840 mg every 2
 weeks or 1200 mg every 3 weeks or 1680 mg every 4 weeks. Tecentriq is administered
 intravenously over 60 minutes until disease progression or unacceptable toxicity.
- Refer to the Tecentriq drug label for dosing for all its other indications.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.